Groupe d'Etude en Oncologie du Quebec

Titre	Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response
Protocole ID	AHOD1721 (CA209-744)
ClinicalTrials.gov ID	NCT02927769
Type(s) de cancer	Pédiatrique divers
Phase	Phase II
Stade	Récidivant/réfractaire (2ième ligne de traitement et plus)
Type étude	Traitement
Médicament	Nivolumab + Brentuximab Vedotin
Institution	CENTRE UNIVERSITAIRE DE SANTE MCGILL HOPITAL DE MONTREAL POUR ENFANTS 1001 boul. Décarie , Montréal, QC, H4A 3J1
Ville	Montréal
Investigateur(trice) principal(e)	Dre Sharon Abish
Coordonnateur(trice)	Katia Pamphile 514-412-4400 poste 22592
Statut	Actif en recrutement
Critètes d'éligibilité	Classic Hodgkin Lymphoma (cHL), relapsed or refractory Minimal limitation on activities of daily living as measured by Karnofsky ≥ 50 for participants > 16 years of age or Lansky ≥ 50 for participants ≤ 16 years of age. One prior anti-cancer therapy that did not work
Critètes d'exclusion	Active, known, or suspected autoimmune disease or infection Active cerebral/meningeal disease related to the underlying malignancy More than one line of anti-cancer therapy or no treatment at all Received a stem cell transplant for Hodgkin Lymphoma and/or a solid organ transplant Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors) Other protocol defined inclusion/exclusion criteria could apply

Groupe d'étude en oncologie du Québec